BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 21140203)

  • 1. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers.
    Shima K; Morikawa T; Baba Y; Nosho K; Suzuki M; Yamauchi M; Hayashi M; Giovannucci E; Fuchs CS; Ogino S
    Cancer Causes Control; 2011 Feb; 22(2):301-9. PubMed ID: 21140203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer.
    Ogino S; Hazra A; Tranah GJ; Kirkner GJ; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Meyerhardt JA; Hunter DJ; Fuchs CS
    Carcinogenesis; 2007 Sep; 28(9):1985-90. PubMed ID: 17621591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.
    Nosho K; Kawasaki T; Ohnishi M; Suemoto Y; Kirkner GJ; Zepf D; Yan L; Longtine JA; Fuchs CS; Ogino S
    Neoplasia; 2008 Jun; 10(6):534-41. PubMed ID: 18516290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma.
    Suehiro Y; Wong CW; Chirieac LR; Kondo Y; Shen L; Webb CR; Chan YW; Chan AS; Chan TL; Wu TT; Rashid A; Hamanaka Y; Hinoda Y; Shannon RL; Wang X; Morris J; Issa JP; Yuen ST; Leung SY; Hamilton SR
    Clin Cancer Res; 2008 May; 14(9):2560-9. PubMed ID: 18451217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.
    Shima K; Nosho K; Baba Y; Cantor M; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
    Int J Cancer; 2011 Mar; 128(5):1080-94. PubMed ID: 20473920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events.
    de Vogel S; Weijenberg MP; Herman JG; Wouters KA; de Goeij AF; van den Brandt PA; de Bruïne AP; van Engeland M
    Ann Oncol; 2009 Jul; 20(7):1216-22. PubMed ID: 19164452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
    Kure S; Nosho K; Baba Y; Irahara N; Shima K; Ng K; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
    Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2765-72. PubMed ID: 19789368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.
    Nosho K; Irahara N; Shima K; Kure S; Kirkner GJ; Schernhammer ES; Hazra A; Hunter DJ; Quackenbush J; Spiegelman D; Giovannucci EL; Fuchs CS; Ogino S
    PLoS One; 2008; 3(11):e3698. PubMed ID: 19002263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.
    Rosty C; Young JP; Walsh MD; Clendenning M; Sanderson K; Walters RJ; Parry S; Jenkins MA; Win AK; Southey MC; Hopper JL; Giles GG; Williamson EJ; English DR; Buchanan DD
    PLoS One; 2013; 8(6):e65479. PubMed ID: 23785428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis.
    Nagasaka T; Goel A; Notohara K; Takahata T; Sasamoto H; Uchida T; Nishida N; Tanaka N; Boland CR; Matsubara N
    Int J Cancer; 2008 Jun; 122(11):2429-36. PubMed ID: 18240147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer.
    Ogino S; Kawasaki T; Kirkner GJ; Suemoto Y; Meyerhardt JA; Fuchs CS
    Gut; 2007 Nov; 56(11):1564-71. PubMed ID: 17339237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions.
    Naito T; Nosho K; Ito M; Igarashi H; Mitsuhashi K; Yoshii S; Aoki H; Nomura M; Sukawa Y; Yamamoto E; Adachi Y; Takahashi H; Hosokawa M; Fujita M; Takenouchi T; Maruyama R; Suzuki H; Baba Y; Imai K; Yamamoto H; Ogino S; Shinomura Y
    World J Gastroenterol; 2014 Aug; 20(29):10050-61. PubMed ID: 25110432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer.
    Tanaka N; Huttenhower C; Nosho K; Baba Y; Shima K; Quackenbush J; Haigis KM; Giovannucci E; Fuchs CS; Ogino S
    Am J Pathol; 2010 Dec; 177(6):2731-40. PubMed ID: 21037082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa.
    Hawkins NJ; Lee JH; Wong JJ; Kwok CT; Ward RL; Hitchins MP
    Mod Pathol; 2009 Dec; 22(12):1588-99. PubMed ID: 19734844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.
    Rosty C; Young JP; Walsh MD; Clendenning M; Walters RJ; Pearson S; Pavluk E; Nagler B; Pakenas D; Jass JR; Jenkins MA; Win AK; Southey MC; Parry S; Hopper JL; Giles GG; Williamson E; English DR; Buchanan DD
    Mod Pathol; 2013 Jun; 26(6):825-34. PubMed ID: 23348904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.
    Imamura Y; Lochhead P; Yamauchi M; Kuchiba A; Qian ZR; Liao X; Nishihara R; Jung S; Wu K; Nosho K; Wang YE; Peng S; Bass AJ; Haigis KM; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
    Mol Cancer; 2014 May; 13():135. PubMed ID: 24885062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.
    Shima K; Morikawa T; Yamauchi M; Kuchiba A; Imamura Y; Liao X; Meyerhardt JA; Fuchs CS; Ogino S
    PLoS One; 2011; 6(9):e25062. PubMed ID: 21949851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients.
    Bagci B; Sari M; Karadayi K; Turan M; Ozdemir O; Bagci G
    Cancer Biomark; 2016 Jun; 17(2):133-43. PubMed ID: 27540971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of catechol-O-methyltransferase gene variants on methylation status of P16 and MGMT genes and their downregulation in colorectal cancer.
    Wani HA; Majid S; Bhat AA; Amin S; Farooq R; Bhat SA; Naikoo NA; Beigh MA; Kadla SA
    Eur J Cancer Prev; 2019 Mar; 28(2):68-75. PubMed ID: 30379684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.